

Health-care industry leader poised to accelerate the Company's global growth plans

MISSISSAUGA, Ontario--([BUSINESS WIRE](#))--MedX Health Corporation ("MedX" or the "Company") (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Sylvain Desjeans has been appointed as the Company's President and Chief Executive Officer, effective immediately.

With more than 30 years of health-care and pharmaceutical industry experience, Mr. Desjeans served in successively senior roles at organizations such as Aspen Pharmacare Canada, Accucaps Industries Limited and Biovail Pharmaceuticals. He has a long track record of successfully executing large-scale growth plans and global product licensing initiatives.

Mr. Desjeans joined MedX on May 5, 2021, as Chief Revenue Officer, and has been working on the Company's market opportunities, including the application of the MedX Dermsecure® platform's artificial intelligence features, as well as initiatives focussed on revenue generation.

His appointment follows a comprehensive recruitment process led by the MedX Board of Directors. "Sylvain brings extensive knowledge of, and experience in, the global medical technology market," said Rob von der Porten, Chairman of the MedX Board of Directors. "As a leader, he is exceptional at building sales, opening distribution channels and developing high-performing teams that deliver results, all of which are imperative for MedX to achieve our growth plans in Canada, the US and internationally."

Sylvain Desjeans stated, "I am honoured at this appointment, and I look forward to helping MedX realize its potential during a time of substantial growth for the Company. We've learned from the challenges of the COVID-19 pandemic that there is a strong need for increasing access and speed to healthcare for patients. I'm energized by the fact that our products are uniquely positioned to maintain a leadership position in this industry. Ultimately, our purpose at MedX is to save lives."

MedX's leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX's SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin's surface.

Teledermatology, is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments. As the world continues to navigate through ongoing COVID-19 recovery measures, teledermatology's advancement has never been more critical to patient care and outcomes.

About MedX:

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit <https://medxhealth.com>.

Forward Looking Statements:

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210812005281/en/>

Contacts

Investor and Media Contacts:

Bill Mitoulas

MedX Health Corp.

 bill@medxhealth.com

416-479-9547